NCT07523581Phase 2Recruiting

EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety

Study sponsor: Eloxx Pharmaceuticals, Inc. · ELOX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06-30Estimated

Enrollment · participants24Estimated

Source updated2026-07-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-10 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Alport Syndrome, X-Linked; Alport Syndrome, Autosomal Recessive

Treatments or interventions studied

ExalurenDrug

Primary outcomes · main study measures

measure: The change in the degree of podocyte foot process effacement; description: Measured in kidney biopsies by the change in the Filtration Slit Density (FSD); timeFrame: Baseline to Week 16; measure: The change in the degree of podocyte foot process effacement; description: Measured in kidney biopsies by the change in the Filtration Slit Density (FSD); timeFrame: Baseline to Week 32

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history